Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
63.94 USD
-2.65%
Market Closed
Updated:
May 29, 2024
Gilead Sciences Inc
Depreciation & Amortization
|
Gilead Sciences Inc
Depreciation & Amortization Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
37%
|
CAGR 10-Years
26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$4.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Depreciation & Amortization
$579m
|
CAGR 3-Years
146%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$196m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$435.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
See Also
What is Gilead Sciences Inc's Depreciation & Amortization?
Depreciation & Amortization
2.7B
USD
2.7B
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Depreciation & Amortization amounts to 2.7B USD.
What is Gilead Sciences Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
18%
18%
Over the last year, the Depreciation & Amortization growth was 24%. The average annual Depreciation & Amortization growth rates for Gilead Sciences Inc have been 20% over the past three years , 14% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
